Concord Biotech Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	76.55	121.86	9.05	151.42	34.99	6.67
Short-Term Investments	4,381	176.33	179.89	228.22	305.8	872.5
Trading Asset Securities	-	4,021	3,165	2,437	1,369	734.73
Cash & Short-Term Investments	4,458	4,319	3,354	2,817	1,710	1,614
Cash Growth	34.52%	28.75%	19.09%	64.71%	5.96%	-19.76%
Accounts Receivable	4,125	4,602	5,217	3,496	2,738	2,322
Other Receivables	-	101.51	210.46	193.66	217.95	272.74
Receivables	4,125	4,703	5,427	3,690	2,956	2,594
Inventory	3,978	3,264	2,397	2,080	2,123	1,951
Prepaid Expenses	-	75.58	73.91	73.31	55.19	47.61
Other Current Assets	346.43	139.68	100.48	303.06	433.05	119.5
Total Current Assets	12,907	12,501	11,352	8,962	7,277	6,327
Property, Plant & Equipment	8,729	8,661	8,442	7,865	7,655	6,436
Long-Term Investments	995.77	891.72	347.62	20.7	79.25	2.56
Goodwill	4.51	3.96	-	-	-	-
Other Intangible Assets	51.86	14.25	11.22	3.2	1.98	35.77
Long-Term Deferred Tax Assets	36.54	29.37	-	-	-	-
Other Long-Term Assets	545.01	246.29	189.05	156.1	126.8	327.4
Total Assets	23,270	22,347	20,343	17,007	15,140	13,128

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Accounts Payable	1,121	1,019	1,130	944.35	938	831.06
Accrued Expenses	-	230.24	192.07	168.21	146.19	131.45
Short-Term Debt	-	-	3.81	-	-	43.37
Current Portion of Long-Term Debt	-	-	-	62.3	250	250
Current Portion of Leases	2.85	8.82	19.58	16.21	1.47	15.96
Current Income Taxes Payable	2.19	0.09	101.27	54.94	89.99	-
Current Unearned Revenue	-	-	-	-	13.13	32.72
Other Current Liabilities	890.71	432.53	393.5	175.55	479.67	247.1
Total Current Liabilities	2,017	1,691	1,841	1,422	1,918	1,552
Long-Term Debt	-	-	-	-	62.36	312.49
Long-Term Leases	14.65	14.33	6.3	18.87	1.64	3.11
Long-Term Deferred Tax Liabilities	486.4	453.59	340.22	280.65	234.39	209.71
Other Long-Term Liabilities	32.77	37.2	28.2	19.56	22.97	18.74
Total Liabilities	2,551	2,196	2,215	1,741	2,240	2,096

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Common Stock	104.62	104.62	104.62	104.62	104.62	95.11
Additional Paid-In Capital	-	819.71	819.71	819.71	819.71	829.22
Retained Earnings	-	19,250	17,203	14,342	11,976	10,108
Comprehensive Income & Other	20,653	-4.01	-	-	-	-
Total Common Equity	20,758	20,171	18,127	15,266	12,900	11,032
Minority Interest	-38.78	-19.23	-	-	-	-
Shareholders' Equity	20,719	20,151	18,127	15,266	12,900	11,032
Total Liabilities & Equity	23,270	22,347	20,343	17,007	15,140	13,128

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Total Debt	17.5	23.16	29.69	97.38	315.46	624.93
Net Cash (Debt)	4,440	4,296	3,325	2,719	1,395	988.98
Net Cash Growth	34.65%	29.20%	22.26%	94.98%	41.02%	-11.58%
Net Cash Per Share	42.23	41.06	31.78	25.99	13.33	9.45
Filing Date Shares Outstanding	106.25	104.62	104.62	104.62	104.62	104.62
Total Common Shares Outstanding	106.25	104.62	104.62	104.62	104.62	104.62
Working Capital	10,890	10,810	9,512	7,541	5,359	4,775
Book Value Per Share	195.37	192.81	173.27	145.93	123.31	105.45
Tangible Book Value	20,701	20,152	18,116	15,263	12,898	10,996
Tangible Book Value Per Share	194.84	192.63	173.17	145.90	123.29	105.11
Land	-	629.93	629.93	547.11	547.11	547.11
Buildings	-	3,732	3,553	2,576	2,463	2,226
Machinery	-	7,097	6,622	4,979	4,788	4,285
Construction In Progress	-	781.59	501.31	2,115	1,727	741.55